mRNA Sequencing Classifier for Non-Invasive IPF Subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Diagnosing idiopathic pulmonary fibrosis (IPF) is challenging due to the need for invasive procedures like surgical lung biopsy and the variability in pathologist interpretations, with existing methods lacking accuracy and accessibility, especially in differentiating usual interstitial pneumonia (UIP) from non-UIP.
Innovation Solution
A nucleic acid sequencing method involving mRNA analysis, including reverse transcription and sequencing, with gene expression profiling and classifiers to differentiate between UIP and non-UIP using specific gene transcripts and sequence variants, potentially aided by machine learning algorithms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If surgical lung biopsy is performed to confirm IPF diagnosis, then diagnostic accuracy is improved, but patient trauma and procedural risk increase
Solution Approach 1:
The patent replaces the mechanical/invasive surgical lung biopsy procedure with a molecular biology-based sequencing system. Instead of physically obtaining and analyzing tissue samples through surgery, the invention uses mRNA sequencing to detect disease-specific gene expression patterns, thereby eliminating surgical trauma while maintaining diagnostic capability
Solution Approach 2:
The patent introduces mRNA sequencing as an intermediary diagnostic method between clinical suspicion and definitive diagnosis. Rather than directly performing invasive biopsy, the system uses molecular markers (mRNA transcripts) as intermediaries to infer disease state, reducing the need for direct tissue sampling
2Reliability
If multidisciplinary team review is implemented to improve diagnostic accuracy, then diagnosis reliability is improved, but time consumption and accessibility worsen
Solution Approach 1:
The patent creates a standardized molecular diagnostic protocol that copies the expertise of multidisciplinary teams into an automated sequencing system. The classifier algorithms encode diagnostic knowledge from experts into computational models, allowing consistent application without requiring actual expert review for each case
Solution Approach 2:
The patent transforms the diagnostic process from a time-intensive human review process to a rapid molecular analysis process. By changing the diagnostic parameters from histopathological evaluation to mRNA expression profiling, the system achieves high reliability through molecular markers while reducing time consumption through automated sequencing and classification
3Measurement precision
If invasive procedures are used to differentiate UIP from non-UIP, then diagnostic precision is improved, but patient morbidity increases
Solution Approach 1:
The patent substitutes mechanical tissue sampling and histological examination with molecular sequencing analysis. By detecting disease-specific mRNA expression patterns in the lung, the system achieves precise differentiation between UIP and non-UIP without requiring invasive procedures that cause patient morbidity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances diagnostic accuracy and reduces the need for invasive procedures by providing a reliable, accessible method to differentiate UIP from non-UIP, facilitating timely and precise IPF diagnosis.
Implementation Method 1
subjecting the plurality of messenger ribonucleic acid molecules to reverse transcription to yield a plurality of complementary deoxyribonucleic acid molecules
Data Source
AI summary
The present invention provides methods for sequencing and analysis of nucleic acids and determining that a subject is positive for a non-usual interstitial pneumonia subtype.